Medivation Inc. is focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation’s goal is to transform the treatment of these diseases and offer hope to critically ill patients and their families. With the approval of Xtandi (enzalutamide) capsules in late August 2012 and the product launch immediately following, Medivation is continuing to build and develop a world-class workforce to take the company to the next strategic level. Medivation was founded in 2004 by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical and biotechnology industries. They founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Medivation is a rapidly growing company with 500+ employees located in beautiful downtown San Francisco, CA.
Parent Company
San Francisco, US
Medivation was founded in 2004 and is headquartered in San Francisco, US

Medivation Office Locations

Medivation has offices in San Francisco, Washington, New York and Jersey
San Francisco, US (HQ)
525 Market St

Medivation Metrics

Medivation Summary

Founding Date

Medivation is a subsidiary of Pfizer

Medivation Financial Metrics

FY, 2013FY, 2014

Operating expense total

$295.2 m$428.6 m


($22.2 m)$281.8 m

Net Income

($42.6 m)$276.5 m
FY, 2013FY, 2014FY, 2015


$228.8 m$502.7 m$225.9 m

Accounts Receivable


$18 m$12.3 m$15.9 m

Current Assets

$354 m$721.9 m$634.2 m


$17 m$41.2 m$58.1 m


$10 m$18.6 m

Total Assets

$392.7 m$911.6 m$1.4 b

Accounts Payable

Current Liabilities

$95.7 m$119.7 m$266.1 m

Additional Paid-in Capital

$410.4 m$506.2 m$684.8 m

Retained Earnings

($334.2 m)($57.7 m)$186.2 m

Total Equity

$76.9 m$449.3 m$872.7 m

Financial Leverage

5.1 x2 x1.6 x
FY, 2013FY, 2014FY, 2015

Net Income

($42.6 m)$276.5 m$244.7 m

Accounts Receivable


($4 m)$301 k($4.6 m)

Accounts Payable

$1.7 m

Cash From Operating Activities

($68.2 m)$273.9 m

Purchases of PP&E

($7.5 m)($10.5 m)($19.5 m)

Cash From Investing Activities

$216.8 m($17.5 m)($431 m)

Short-term Borrowings

($12 k)

Cash From Financing Activities

$8.9 m$50.8 m($65.8 m)

Interest Paid

$6.8 m$6.8 m$3.6 m

Income Taxes Paid

($127 k)$1.5 m$2.1 m

Medivation News

Medivation Company Life

You may also be interested in